Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer
1 other identifier
observational
30
1 country
1
Brief Summary
This project aims to comprehensively analyze the diagnostic efficacy of SUVmax, SUVean, TLG, MTV, etc. in gastric cancer through 18F-FAPI-04 PET/CT imaging combined with serum tumor markers and other methods, and construct a molecular imaging diagnostic model for gastric cancer; Next, analyze the diagnostic efficacy of 18F-FAPI-04 PET/CT and PET/MR multimodal imaging in evaluating SUVmax, PET/CT-PCI, and PET/MR-PCI for gastric cancer peritoneal metastasis, and construct a molecular imaging diagnostic model for gastric cancer peritoneal metastasis; Exploring the clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2024
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2024
CompletedFirst Submitted
Initial submission to the registry
August 3, 2024
CompletedFirst Posted
Study publicly available on registry
August 7, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2028
August 7, 2024
March 1, 2024
3 years
August 3, 2024
August 3, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
18F-FAPI-04 PET imaging diagnosis of gastric cancer detection rate
Exploring the feasibility of using targeted fibroblast activation protein (FAP) PET/CT imaging for gastric cancer; Compare the advantages and disadvantages of 18F-FAPI-04 and 18F-FDG in gastric cancer imaging, explore the clinical application value of 18F-FAPI-04 PET/CT in gastric cancer imaging, and construct a molecular imaging diagnostic model for gastric cancer
2 years
Secondary Outcomes (1)
Detection rate of peritoneal metastasis in gastric cancer
2 years
Interventions
The clinical value of 18F-FAPI-04 PET/CT and PET/MR imaging in the diagnosis and staging of gastric cancer
Eligibility Criteria
Gastric cancer
You may qualify if:
- Age over 18 years old;
- Diagnosed as a patient with gastric cancer;
- Receive FAPI PET/CT and FDG PET/CT imaging within one week;
- Perform serum tumor marker testing one week before and after scanning
You may not qualify if:
- History of other malignant tumors;
- Patients with severe infections, severe underlying diseases such as heart, kidney, and liver;
- Patients with contraindications for PET-CT examination, poor physical condition, and inability to tolerate the examination;
- Patients with unorganized pathology or incomplete clinical data
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hunan Cancer hospital
Changsha, Hunan, 410000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
August 3, 2024
First Posted
August 7, 2024
Study Start
January 1, 2024
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2028
Last Updated
August 7, 2024
Record last verified: 2024-03
Data Sharing
- IPD Sharing
- Will not share